<DOC>
	<DOCNO>NCT00914628</DOCNO>
	<brief_summary>The main objective randomize trial compare disease-free survival ( DFS ) high risk leukemia patient underwent haploidentical HCT follow add back strategy HSV-Tk donor lymphocytes standard haploidentical HCT</brief_summary>
	<brief_title>TK008 : Efficacy Study Strategy HSV-Tk Engineering Donor Lymphocytes Treat Patients With High Risk Acute Leukemia</brief_title>
	<detailed_description>Delayed immune-reconstitution remain one main limitation haploidentical stem cell transplantation . The risk severe infection remain high several month CD3+ reconstitution could take 10 month . The low number lymphocyte infuse graft , degree HLA ( Human Leukocyte Antigen ) disparity , reduce thymic function adult difference host/donor antigen present cell contribute cause . The infusion HSV-TK engineer lymphocyte may represent significant therapeutic improvement haploidentical HCT ( hematopoietic cell transplantation ) , remarkably may enhance GvL ( Graft versus Leukemia ) activity , thus reduce occurrence disease relapse , post-transplant immune reconstitution absence chronic immune suppression , thus decrease rate post-transplant opportunistic infection transplant-related mortality . Furthermore , efficient control GvHD achieve via suicide mechanism allow also multiple infusion HSV-TK-treated donor lymphocyte , need , might improve post-transplant host immune reconstitution , survival patient receive haplo-HCT . Finally , therapeutic approach become valuable option candidate , include patient advanced disease old age . The proposed clinical trial represent innovative therapeutic treatment patient affect high risk acute leukemia , undergone haploidentical stem cell transplantation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>Age ≥ 18 year HCT comorbidity index &lt; 3 Any following condition : AML ALL 1st complete remission ( CR ) high risk relapse base negative prognostic factor ( definition highrisk relapse see Appendix H ) . AML ALL 2nd subsequent CR Secondary AML CR secondary AML ALL 1st 2nd relapse primary refractory Absence timely suitable fully HLA match one HLA locus mismatch family unrelated donor , Investigator 's discretion , absence possible therapeutic alternative Stable clinical condition life expectancy &gt; 3 month PS ECOG &lt; 2 Patients , legal guardian , donor must sign informed consent indicate aware research study tell possible benefit toxic side effect Serum creatinine &lt; 1.5 x ULN Bilirubin &lt; 1.5 x ULN ; transaminases &lt; 3 x ULN Left ventricular ejection fraction &gt; 45 % QTc interval &lt; 450 m DLCO &gt; 50 % Patients lifethreatening condition complication basic condition Contraindication haploidentical HCT define Investigator Patients active CNS disease Pregnant lactation . Exclusion criterion HSVTk infusion : Infections require administration ganciclovir , valganciclovir acyclovir time infusion : HSVTk cell administer 24hour discontinuation interval antiviral therapy GvHD require systemic immunosuppressive therapy Ongoing systemic immunosuppressive therapy haploidentical HCT Administration GCSF haploidentical HCT CD3+ cell ≥ 100/µl day plan experimental infusion haploidentical HCT Any grade 34 adverse event relate HSVTk infusion grade 2 adverse event resolve grade 1 next infusion For criterion 2 , 3 4 : HSVTk cell administer adequate patient washout period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>high risk acute leukemia</keyword>
	<keyword>HSV-TK</keyword>
	<keyword>Haploidentical HCT</keyword>
	<keyword>GvHD</keyword>
	<keyword>GvL</keyword>
	<keyword>Immunoreconstitution</keyword>
</DOC>